Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment

NCT00446485 is registered in ClinicalTrials.gov with Milsing d.o.o. as lead sponsor.

NCT NCT00446485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00446485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ginkgo Biloba Standardized Extract (24% Ginkoflavonoglicozides and 6% Terpenes) in Treatment of Mild Cognitive and Concentration Impairment
Lead sponsor
Milsing d.o.o.
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2007
Completion date
April 30, 2010
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cerebrovascular insufficiency, mild cognitive impairment